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Natural killer cells possess key regulatory function in various malignant diseases, including
acute myeloid leukemia. NK cell activity is driven by signals received through ligands
binding activating or inhibitory receptors. Their activity towards elimination of transformed
or virally infected cells can be mediated through MICA, MICB and ULBP ligands binding
the activating receptor NKG2D. Given the efficiency of NK cells, potential target cells
developed multiple protecting mechanisms to overcome NK cells killing on various levels
of biogenesis of NKG2D ligands. Targeted cells can degrade ligand transcripts via
microRNAs or modify them at protein level to prevent their presence at cell surface via
shedding, with added benefit of shed ligands to desensitize NKG2D receptor and avert
the threat of destruction via NK cells. NK cells and their activity are also indispensable
during hematopoietic stem cell transplantation, crucial treatment option for patients with
malignant disease, including acute myeloid leukemia. Function of both NKG2D and its
ligands is strongly affected by polymorphisms and particular allelic variants, as different
alleles can play variable roles in ligand-receptor interaction, influencing NK cell function
and HSCT outcome differently. For example, role of amino acid exchange at position 129
in MICA or at position 98 in MICB, as well as the role of other polymorphisms leading to
different shedding of ligands, was described. Finally, match or mismatch between patient
and donor in NKG2D ligands affect HSCT outcome. Having the information beyond
standard HLA typing prior HSCT could be instrumental to find the best donor for the
patient and to optimize effects of treatment by more precise patient-donor match. Here,
we review recent research on the NKG2D/NKG2D ligand biology, their regulation,
description of their polymorphisms across the populations of patients with AML and the
influence of particular polymorphisms on HSCT outcome.
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Acute myeloid leukemia (AML) is an aggressive malignancy
originated from a myeloid lineage of bone marrow cells with
median overall survival of 8.5 months and 24% 5-year overall
survival according to National Cancer Institute in the USA (1, 2).
Most patients with AML achieve complete remission after
chemotherapy treatment, but relapse is almost inevitable and
often indicates the appearance of treatment-resistant clones (3).
Carrying specific gene mutations enable drug-resistance,
survival, and uncontrolled proliferation. However, for the
disease progression, AML cells also need to escape immune
system control. Healthy immunosurveillance should eliminate
AML cells by using two main effector cells types that play pivotal
and complementary role in this mechanism - T lymphocytes and
natural killer (NK) cells. Unlike T cells, whose function depends
on the recognition of “non-self” peptides presented on HLA
molecules, NK cells recognize cells with or without the altered
level of HLA molecules and thus can recognize transformed cells
that hide these molecules as a mechanism of escape T-cells (4).
Besides direct attack targeted to transformed cells, NK cells also
compete with myeloid leukemic blasts to colonize the bone
marrow niche and to adhere to bone marrow fibroblasts,
preventing myeloid blasts from proliferation (5).
Interaction between AML and NK cells exists in both
directions, as AML cells use multiple mechanisms to protect
themselves, including modification of NK cells in patients.
Individuals with AML have low levels of cytotoxic NK cells,
usually combined with decreased expression levels of activating
receptors, for example, NKp46 (6), NKp30 (7), NKG2D (6) or
DNAM-1 (8, 9). In contrast, inhibitory receptors tend to be
increased, for example a decreased DNAM-1 is being associated
with increased expression of inhibitory receptors TIGIT and/or
TACTILE (9). Another inhibitory receptors implicated in NK
cells’ tolerance to the AML blasts are inhibitory KIR, NKG2A,
CD158b, and LIR-1 (6, 10). In addition, AML cells express a high
amount of soluble activating receptors’ ligands responsible for
NK cells silencing through downregulation of their receptors by
chronic exposure causing exhaustion of NK cells (11).
To overcome immunosurveillance impairment caused by
malignant cells, hematopoietic stem cells transplantation
(HSCT) is an essential treatment option for patients with
relapsed AML. NK cells have a crucial role in the success of
HSCT by affecting host, graft, and residual leukemic cells. The
graft-versus-leukemia (GvL) effect of NK cells was already
described in 1986 (12). In addition, NK cells decrease the
incidence of graft-versus-host disease (GvHD) by reduction of
antigen-presenting cells, and elimination of host T cells,
preventing graft rejection (13).
To take full advantage of their potential, it is crucial to
understand the mechanisms of ligand-receptor functions and
to know better the parameters, which can influence the outcome
of HSCT. Balance of NK cells reactivity depends on the
combination of signals transduced from inhibitory and
activating receptors and their ligands present on “examined”
cells. Main and broadly investigated inhibitory and activating
receptors of NK cells are KIR receptors which recognize HLAFrontiers in Immunology | www.frontiersin.org 2class I-bearing targets, while activating natural cytotoxic
receptors (NCR), namely NKp30, NKp44 and NKp46, DNAM-
1 and NKG2D recognize non-HLA molecules and ligands
expressed de novo on “stressed” cells (14–17).
This review focuses on activating NKG2D receptor, its
l igands, their regulation, and on the role of their
polymorphism in AML patients and dependency of the
polymorphism of NKG2D and its ligands on HSCT outcome.NKG2D RECEPTOR
NKG2D (encoded by the KLRK1 gene – killer cell lectin-like
receptor subfamily K, member 1) is a C-type lectin receptor
present on the surface of natural killer (NK) cells, gd T cells,
CD8+ T cells and CD4+ T cells (18–20).
KLRK1 is composed of 10 exons (exons 1A, 1B, and 2–9) and
9 introns, with exons 2–4 encoding intracellular/transmembrane
domain and exons 5–9 encoding the ligand-binding outer
domain, which is exposed into the extracellular space (21).
NKG2D receptor recognizes and binds multiple ligand
families, and upon ligand’s engagement it interacts with
adapter dimer DAP10, which triggers activation signal leading
to cell-mediated cytotoxicity (degranulation), co-stimulation of
cytokine production, playing an important role in the tumorous
and infected cells elimination (18, 22, 23).
Although NKG2D shows strong evolutionary conservation,
two different haplotype blocks have been described. Haplotype
block Hb-1 contains two alleles called LNK1 (low-activity
related) and HNK1 (high-activity related), in three haplotype
combinations – LNK1/LNK1, HNK1/HNK1, and LNK1/HNK1.
For haplotype block Hb-2, the situation is similar with
haplotypes containing LNK2 and HNK2 alleles (24).
From a clinical perspective, HNK1/HNK1 and HNK2/HNK2
haplotypes seem to be associated with lower cancer risk than
LNK1/LNK1 and LNK2/LNK2, respectively (24). NKG2D
receptor haplotypes also show a significant impact on
transplantation outcomes. Patients with standard-risk
hematology malignancy (AML and acute lymphoblastic
leukemia, ALL in first complete remission, malignant
lymphoma in complete remission, chronic myeloid leukemia,
CLL in chronic phase and any status of a myelodysplastic
syndrome) undergoing HSCT with HNK1 haplotype donor
have lower transplantation-related mortality and better overall
survival (difference in 5-year overall survival of 73% vs. 49%,
p=0.01) (18). NKG2D haplotype also represents a candidate
biomarker for the prediction of treatment-free remission,
described currently in patients with CML treated by dasatinib,
where patients with HNK1/HNK1 haplotype achieved molecular
response faster than patients with other haplotypes (25).
As mentioned in the Introduction, AML cells can modify the
expression of activating receptor of NK cells, including the
NKG2D receptor, as described by Hilpert et al. in 2012 (26).
Khaznadar and colleagues investigated AML patients, dividing
them into two groups according to clinical outcome. The group
with deficient NK cell profile (NK-DP), reduced expression ofMarch 2021 | Volume 12 | Article 651751
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higher risk of relapse, while the group with NK cell-high profile
(NK-HP) had a significantly lower risk of relapse and better
median overall survival (HR 0.66, 95% CI 0.44-0.99) (27).NKG2D LIGAND
NKG2D ligands in human can be divided into two families -
MIC (MHC class I-related chain) family and ULBP/RAET
(HCMV Unique Long 16-binding protein/Retinoic acid early
transcript) family. Both are distant HLA class I homologues but
do not associate with b-2 microglobulin and have no known role
in antigen presentation (26).
NKG2D ligands are called stress-ligands as their presence is
stimulated predominantly in damaged, virally infected, or
tumorous cells (27). Besides of these stimuli, these ligands can
be upregulated by standard cell-stress conditions including heat
shock (28), oxidative stress (29), and ionizing radiation (28, 30).
NKG2D ligands are also expressed on healthy conditions,
particularly on proliferative cells like embryonic cells (31),
myeloid progenitors (32), normal intestinal epithelial cells (33),
or cells of repairing tissue (34). The mechanisms protecting these
cells against NK cell attack are not fully known. It seems that on
healthy cells, NKG2D ligands alone is not sufficient signal to
trigger NK cell activation (35). The intracellular localization of
NKG2D ligand is an additional observed protecting mechanism
causing ligand’s inaccessibility to the receptor (33, 35). On the
other hand, the presence of NKG2D ligands on immune cells also
plays an important role in regulating immune responses (36).
The polymorphism of NKG2D ligands genes affects
susceptibility to different diseases (37), disease severity (38),
transplantation outcome (organ or HSCT), and serves as a risk
factor (39) and/or as protective factor for cancer (40).
MIC Family
MIC family comprises 7 genes, from which only two are
expressed (MICA and MICB) and an additional five being
considered as pseudogenes (MICC, MICD, MICE, MICF, and
MICG) (41).
BothMICA andMICB contain 6 exons and 5 introns - exon 1
encodes leader sequence, exons 2 - 4 encode three extracellular
domains a1, a2, and a3, exon 5 encodes the transmembrane
region and exon 6 encodes the cytoplasmic tail. The majority of
polymorphisms of MICA and MICB alleles are concentrated on
exons 2, 3, 4, and 5, predominantly within a2 and a3 domains
(Figure 1) (41, 42).
In the current literature, there are two different nomenclature
approaches for MICA allele description (summarized in
Figure 2).
The first approach is based on a sequence of exon 5, called
exon 5 (EX5) microsatellite alleles’ group, and corresponds to a
repeated sequence of 4 to 10 Ala (GCT) codons within this exon,
with alleles named A4, A5, A5.1, A6-10. A5.1 MICA alleles are
specific by having additional guanine nucleotide insertion
between codons 20 and 21, resulting in a premature stopFrontiers in Immunology | www.frontiersin.org 3codon at codon 41 (43). This truncated protein lacks the
cytoplasmic tail encoded by exon 6 (41, 44). This difference is
translated into the form of anchorage of the final protein to the
cell membrane. Most of MICA alleles are transmembrane-
anchored glycoprotein with a cytoplasmic tail; A5.1 alleles
create glycophosphatidylinositol (GPI)-anchored glycoproteins
(45). To date, it is not clear if other microsatellite alleles (A4, A6-
A10) could encode similar truncated proteins too. This feature
seems to arise as a consequence to cytomegalovirus’ (CMV)
immunoevasin UL142 (46). This immunoevasin enables the
immune escape of the infected cells by retaining protein
product of MICA alleles in the Golgi apparatus while not
affecting truncated proteins encoded by MICA A5.1 alleles
(46, 47).
The second nomenclature approach is based on the gene
sequence, but not always all exons have been sequenced. The
sequence alleles nomenclature (for example MICA*008:01:09) is
similar to the HLA World Health Organization nomenclature,
comprising gene name (MICA or MICB), separator (*), allele
group (for example *008), field separator (): specific MICA
protein (two-digit format, for example, 01) and next closer
specification as described at hla.alleles.org/nomenclature/
naming.html (48). This nomenclature approach is used not
only for MICA but also for MICB alleles (48). To date 223
MICA sequence alleles encoding 104 proteins and 138 MICB
alleles encoding 37 proteins have been described (release June
2020) (48).
According to the large study of 1.2 million donors with
German descent, the most common MICA allele in Caucasian
(German) population is MICA*008 (A5.1) with a frequency of
42.3% followed by MICA*002 (A9 microsatellite allele) with
11.7%, and MICA*009 (A6 microsatellite allele) with 8.8%. The
most common MICB allele in the same population is MICB*005
with a frequency of 43.9% followed byMICB*004 with 21.7% and
MICB*002 with 18.9% (49). Taking another populations into
account, MICA*008 is the most frequent MICA allele worldwide
with MICA*002, MICA*009, MICA*010 and MICA*004 taking
next places varying according to inter-ethnic variability (49–51).
Also, MICB results across the population correspond to the
German study, i.e., most frequent is MICB*005 and followed
by MICB*002, MICB*004, MICB*014, and MICB*003 (52).
ULBP Family
All 10 ULBP family members are officially named RAET1 genes
and are orthologs of the mouse Raet1 genes (53). Six genes of
them are expressed (ULBP1 - 6), while 4 are pseudogenes (53).
ULBP1 (RAET1I), ULBP2 (RAET1H), ULBP3 (RAET1N),
ULBP4 (RAET1E) and ULBP6 (RAET1L) have 4 exons while
ULBP5 (RAET1G) comprises 5 exons. Exon 1 encodes leader
sequence, exons 2 and 3 define the a1 and a2 domains, and exon
4 encodes a hydrophobic sequence, both for GPI anchor region
and transmembrane region with the cytoplasmic tail (53–56).
ULBP2 and ULBP5 can form both transmembrane-anchored
and GPI-anchored form, ULBP1, ULBP3 and ULBP6 are only
GPI-anchored and ULBP4 forms just transmembrane-anchored
protein (Table 1) (57, 58). Exon 5 seems to encode for the
extended cytoplasmic domain (ULBP5) or is non-coding (otherMarch 2021 | Volume 12 | Article 651751
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domain (53), which seems to have no effect on NKG2D binding
(53), but it probably precludes CD8 (T cells co-receptor)
binding (59).
ULBP/RAET1 genes seem to be less polymorphic than MIC
genes, although this could be caused by a lower number of
sequenced samples (52). Four out of the six ULBP genes have
been found to be polymorphic in exons 2 and 3, coding
extracellular part of the protein. So far no polymorphism has
been described in ULBP1 and ULBP3 within exons 2 and 3 (52).
The most polymorphic gene is ULBP4 with 11 known alleles
(52), followed by ULBP6 with 7 known alleles, ULBP2 with 6
alleles and ULBP5 with3 described alleles (52, 60). Currently,
ULBP polymorphism has been studied in 223 Euro-Caucasoid,
60 Afro-Caribbean, 52 Indo-Asian individuals (61), Kolla South
American Indians (60) and Thais (62), a broader sampling is
required to achieve a true picture of ULBP polymorphism. For
the Caucasian population, the most common ULBP4 alleleFrontiers in Immunology | www.frontiersin.org 4is *002, while for Thais it is *001, and for Kolla Indians it is
*003 (60). Similarly, ULBP6 alleles frequency also differs between
populations, Caucasians having *003 most often, Thais *001 and
Kolla Indians *002 (60). The variability in the frequency of ULBP
alleles among individual populations seems to be associated with
differences in life conditions and contact with unique
pathogens (60).REGULATION OF NKG2D LIGANDS
As mentioned above, NKG2D ligands are stress-associated
molecules upregulated on damaged or transformed cells to
attract immune cells, especially NK cells. Their expression is
regulated by numerous pathways and signals on multiple levels
of biogenesis - on transcriptional, translational, and post-
translational level (Figure 3).FIGURE 1 | Schematic representation of MICA and MICB structure. MICA and MICB comprise 6 exons and 5 introns (middle) - exon 1 encodes leader sequence,
exons 2 - 4 encode three extracellular domains a1, a2 and a3, exon 5 encodes the transmembrane region and exon 6 encodes cytoplasmic tail (bottom).March 2021 | Volume 12 | Article 651751
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expression is induced initially by hyperproliferative state
occurring during early tumorigenesis. Hyperproliferation
activates E2 transcription factor, which induces NKG2D
ligands’ transcription (34). Hyperproliferative state could also
trigger DNA damage response (63), and so activate p53 (64).
Activated p53 then enhances transcription of NKG2D
ligands (65).
NKG2D ligands’ mRNA usually has a very short half-life; it is
rapidly degraded and needs to be stabilized for translation.
Besides the increased transcription, DNA damage response alsoFrontiers in Immunology | www.frontiersin.org 5plays a role in the mRNA stabilization via signaling protein TBK1
and transcription factor IRF3, which induce conditions that help
to increase the half-life of NKG2D ligands transcripts (66).
In contrast, faster degradation of NKG2D ligand transcripts
can be induced by specific microRNAs that bind to their 3’
untranslated region and repress their translation (67).
MicroRNA regulates stress ligands overexpression, as only
when MICA and MICB mRNA exceeds the microRNA
repression, the NKG2D ligands are expressed on the cell
surface. Overexpression of microRNAs can help tumors to
downregulate NKG2D ligands expression and then escape the
immune system (68).
Another mechanism leading to the reduced levels of surface
NKG2D ligands is via poly-ADP-ribose polymerase 1 (PARP1)
mediated repression of transcription. This mechanism seems to
be specific for leukemia stem cells and enables them to escape
immune surveillance and later to cause relapse of disease (69).
This opens the possibility to use PARP inhibitors for AML
patient (70), an approach that the first clinical trials are
currently assessing (71–73).
At the protein level, NKG2D ligands are regulated by various
post-translational modifications. First, described in MULT1
ligand (mouse homolog of human ULBP1), is ubiquitin-FIGURE 2 | MICA nomenclature. Two types of MICA nomenclature are shown. Top panel, based on microsatellite repeat (GCTn) within exon 5, which encodes a different
number of alanines (A4-10). Bottom pannel, based on sequence of exons 2, 3, 4 and 5 and its nomenclature correspond to HLA nomenclature (MICA*XXX : XX:XX).TABLE 1 | Human NKG2D ligands.
Ligand name Alternative name Number of exons Anchorage type
MICA PERB11.1 6 TM/GPI
MICB PERB11.2 6 TM
ULBP1 RAET1I 4 GPI
ULBP2 RAET1H 4 TM/GPI
ULBP3 RAET1N 4 GPI
ULBP4 RAET1E 4 TM
ULBP5 RAET1G 5 TM/GPI
ULBP6 RAET1L 4 GPITM, transmembrane type; GPI, glycosylphosphatidylinositol-linked type.March 2021 | Volume 12 | Article 651751
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primarily on lysine residues of target proteins (75). The
presence of multiple lysins in the cytoplasmic tail of MICA,
MICB and ULBP5 (RAET1G) suggests that this regulation could
also exist for these human ligands (76). It has been shown, for
example, that KSHV (Kaposi’s sarcoma-associated herpesvirus)
uses E3 ubiquitin ligase K5 to downregulate cell surface
expression of MICA and MICB (77).
A crucial system of NKG2D ligands regulation is the
production of soluble variants of the NKG2D ligands by
various mechanisms - co-transcriptional alternative splicing,
post-translational ligand shedding, exosome ligand excretion
and phospholipase C (PI-PLC) cleavage for ligands anchored
by GPI. Shed ligands passively block NKG2D receptor on the NK
cell, which is then internalized into the cell and degraded, leading
to impairment of its function (78). This mechanism helps cancer
cells to escape immune surveillance by blocking NKG2D and
consequently NK cell activity. Another benefit of released ligands
for cancer cell is that this cell became less visible for NK cells due
to the lower NKG2D ligands’ concentration on its surface (79).
Co-transcriptional regulation by alternative splicing can also
lead to soluble forms of NKG2D ligands, and has been described
for ULBP4 (55) and ULBP5 (54). In RAET1G (ULBP5) it creates
a product RAET1G2, where alternative splicing in exon 4 caused
a frameshift and premature termination of the protein sequence
and thus led to the soluble form of RAET1G (ULBP5) (54). TheFrontiers in Immunology | www.frontiersin.org 6next example was described in ULBP4 (RAET1E) with a product
of spliced variant called RAET1E2 where a stop codon was
placed within intron between exons 3 and 4, producing a
shortened form of ULBP4 (RAET1E) (80).
First, ligand shedding is mediated by two proteases families,
“a disintegrin and metalloproteinase” (ADAMs) family (81) and
matrix metalloprotease family (MMPs) (82, 83). From the
ADAM proteases family, ADAM9, ADAM10 and ADAM17
have been shown to be active in shedding of MICA, MICB and
ULBP2 ligands (84). Matrix metalloproteases are able to shed
ULBP2 (83) or MICA (82, 85). Polymorphism of some NKG2D
ligands can bypass the shedding process; for example, MICA*008
is bound to the membrane through GPI anchor, makes this allele
resistant to protease-mediated cleavage (45).
The second way for cancer cells to remove NKG2D ligands at
the protein level is the use of constitutive production and release
of endosome-derived vesicles called exosomes, which eliminate
active proteins or microRNAs from cells. The NKG2D ligands
are expressed and carried on the surface of tumor exosomes and
released into the environment (86). The NKG2D ligands released
via exosomes have a proven effect on the downregulation of
NKG2D and desensitization of cytotoxic cells (87, 88).
The last mechanism which cells can use to cut off their ligands
is using cleavage via phospholipase release (PI-PLC), described
in GPI anchored ULBP1 (RAET1I), ULBP2 (RAET1H), ULBP3
(RAET1N) and ULBP6 (RAET1L) (89). This mechanism isFIGURE 3 | Regulation of NKG2D ligands. Mechanisms triggering transcription of ligand genes and mRNA stabilization are labeled as green. Processes leading to
mRNA or protein degradation or removal of ligands from cell surface are labeled as red.March 2021 | Volume 12 | Article 651751
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for other types of cancer.
The way of ligands shedding, either by protease cleavage or by
exosomes, is most likely dependent on ligands attachment to the
cell membrane. GPI-anchored MICA alleles vs. other
transmembrane attached MICA alleles could serve as a model –
protein product of MICA*008, GPI-anchored NKG2D ligand, is
not usually cleaved by proteases but is released by exosomes (90).
On the other hand, other transmembrane-attachedMICA,MICB,
or ULBP are primarily released by cleavage (81, 83, 91). Some
ligands, for example ULBP2, can be released by both ways (88).
Solubilization of NKG2D ligands thus can have severe
consequences for cancer patients, as lower cell-surface NKG2D
ligands concentration (83) and presence of soluble NKG2D
ligands in sera, very often, correlate with higher tumor stage and
poor prognosis (84). For example, metalloproteinase ADAM10 is
highly expressed in malignant pleural mesothelioma (92), prostate
cancer (93) or in oral squamous cell carcinoma (94), which makes
all of those tumor types able to escape immune surveillance by
NKG2D ligands shedding.
In general, solubilization of MICA is a widespread mechanism
of NK cell escape in malignant diseases. Holdenrieder et al.
described an increased level of soluble MICA in lung cancer,
colorectal and other gastrointestinal cancers, breast cancer,
ovarian cancer, other gynecologic cancers, renal cancer, and
prostate cancer as mentioned above (79). Paschen et al.
described increased levels of sMICA also in melanoma (95),
while in hematological malignancies, a higher level of sMICA
and sMICB was described in multiple myeloma (96) and various
leukemias (97, 98).NKG2D LIGANDS AND ACUTE
MYELOID LEUKEMIA
As described above, multiple mechanisms enable tumors to escape
immune surveillance with ligand shedding being one of the most
important. In relation to AML, in 2003, a seminal work of Salih
et al. investigated AML blasts and found various NKG2D ligands
expressed on these cells, but they also demonstrated that patients
with AML had significantly elevated levels of soluble MICA and
MICB in comparison with healthy donors (99). This observation
was confirmed nine years later by Hilpert et al., who discovered
that 70% of AML blasts were positive for at least one NKG2D
ligand (with 15% of patients having leukemic cells expressing even
four or five different NKG2D ligands), and in addition, 100% of
patients with AML in this study had detectable serum levels of
NKG2D ligands with MICA being the one most often detected in
the sera (97). In AML patients, also complete absence of surface
expression of NKG2D ligands was described, and it is believed to
be a consequence of malignant cell development (32).
In addition to shedding and no presence of NKG2D ligands
on the cell surface, polymorphisms of NKG2D ligands may play
a role in AML development, although data are still too sparse to
make clear conclusions. Currently, there are only two studies
addressing the relationship between MICA polymorphisms andFrontiers in Immunology | www.frontiersin.org 7leukemia, including acute myeloid leukemia, work of Luo et al.
focused on people of Han nationality of Southern China (100)
and work of Baek et al. on Korean patients (101). There is a need
to extend this type of studies to a wider population to allow for
significant conclusions.
Luo et al. described differences between patients with leukemia
and healthy ethnically matched controls. According to their
observation, homozygotes with microsatellite alleles A5 and
allele MICA*010 have increased risk for developing leukemia
(specifically for AML, the ratio of frequency was 35.9% in patients
with AML vs. 17.6% in control samples). This makes MICA A5 a
risk factor for AML. Ji et al. in their meta-analysis focused on
multiple types of cancer in multiple populations, described alleles
A5 as protective factor for its carrier (40), which seems
contradictory with AML results of Luo et al. It is necessary to
further study the correlation between alleles A5 as a positive or
negative risk factors across multiple populations and specific
cancers. Alleles MICA A5.1 (including the most frequent allele
MICA*008) frequency was decreased in heterozygous leukemic
patients, described only on lymphocytic leukemia, with data for
myeloid leukemia, unfortunately, missing (100).
The other study with data from Korean patients included 324
patients with AML, ALL, and MDS, with 172 AML samples. In
AML patients, the authors observed a higher frequency of MICA
A9 alleles than in the control group (34.9% vs. 22.0%). Although
alleles A9 can be found on a transcript level more frequently in
AML patients, presence of protein product is often reduced on the
cell surface by release or shedding of the ligand from AML cells
and rendering tumor cells less detectable by NK and T cells (101).
Similarly to Han population described above, MICA A5.1 alleles
were found with lower frequency in AML patients than in
controls (25.0% vs 38.0%) (101).
Only a little is known about the relationship between of AML
andMICB. Baek et al. observed a difference between patients and
controls only within one MICB allele, MICB*005:03, with lower
frequency in AML patients (2.9% vs. 10.5%) (101).
In the case of ULBP, only one study analyzed ULBP
polymorphisms and their distribution among patients with
hematological malignancies and among their donors with no
difference in alleles frequency observed. Therefore, ULBP cannot
currently be used as genetic determinants for the risk of
developing a hematological malignancy (61, 102). On the other
hand, although Mastaglio et al . were not assessing
polymorphisms, they described ULBP1 expression on AML
blasts correlating with improved 2-year overall survival,
relapse-free survival, and reduced relapse (103).NKG2D LIGANDS AND
TRANSPLANTATION OF HEMATOPOIETIC
STEM CELLS
Transplantation of hematopoietic stem cells is a standard
treatment of multiple hematology malignancies, as well as non-
malignant diseases (104). The aim of transplantation of HSCT
lies in the graft’s ability to react against residual cancer cellsMarch 2021 | Volume 12 | Article 651751
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(GvL) response (105, 106). Unfortunately, HSCT has several side
effects and most patients experience some serious complications –
acute-graft-versus-host disease (aGvHD), chronic GvHD
(cGvHD) and/or relapse (107, 108). These complications also
negatively impact patients’ quality of life and increase mortality.
GvHD can be described as an exaggerated manifestation of
inflammation based on the interaction between donor
lymphocytes and foreign (i.e., patient’s) antigens (109). The
incidence of GvHD (both types) ranges between 40 to 60%,
with mortality around 15% (109). Chronic GvHD is a major
cause of mortality in long-term survivors of HSCT (110), and
acute GvHD is the second leading cause of death after
HSCT (111).
From a pathophysiology perspective, acute GvHD is caused
by a conditioning regimen that damages target tissue (112). This
damage leads to a cytokine storm which activates antigen-
presenting cells (APC) from the patient (and later also donor’s
APC), that are recognized by donor’s T cells (113). During the
second phase, donor’s T cells are activated by interaction with
APC, and they proliferate and differentiate into helper T cells
Th-1, cytotoxic T cells and Th-17/Tc-17 (114). These activated T
cells then produce additional cytokines, such as IL-2, which
promotes further activation of T cells and also triggers NK cell
responses (115). The last phase is based on escalation of
inflammation resulting in end-organ damage (109). The
mortality risk depends on the stage and grade of aGvHD
(111). Among the most affected organs are the upper and
lower gastrointestinal tracts, liver, and skin. Grading depends
on the combination of damage of these organs (111). A stricter
definition can be found in NIH consensus criteria from
2014 (116).
Chronic GvHD also consists of three phases, and its trigger is
tissue damage caused by aGvHD, another cytotoxic injury or
infection (117). This damage activates innate immune cells but
also non-hematopoietic cells. The second phase is based on the
overreaction of the adaptive immune system going hand in hand
with the reduction of immune cell regulators, such as regulatory
T-cells, causing upregulation of helper T cells Th-1, Th-17 and in
contrast to aGvHD, also Th-2 (117). Phase three consists in
abnormal tissue repair (117). Clinical manifestations can be
similar to autoimmune disorders, it manifests in oral mucosa,
for example, lichen or planus, it attacks eyes, causing, for
example, keratoconjunctivitis secca or uveitis, and it targets
skin, soft tissues, or inner organs (liver, lung disease,
gastrointestinal tract or CNS) (110).
Older definition (currently seldom used) required onset of
symptoms within 100 days for aGvHD and later onset for
cGvHD. This is currently replaced by NIH definition, which is
based on clinical manifestations rather than on the time of the
onset alone (116).
As both GvHD types are potentially dangerous and life-
threatening, all efforts are directed to avoid GvHD completely
or to suppress GvHD manifestation (106). This can be achieved
by a complete match of patient’s and donor’s HLA molecules (10
out of 10) (118). However, the full match can lead to a lower GvLFrontiers in Immunology | www.frontiersin.org 8reaction. The key clinical issue is then minimization of GvHD
and maximization of GvL (119). Some mismatches between
donor and patient in HLA, such as some HLA-DPB1 or
HLA-Cw, can decrease the risk of relapse, which is caused by
GvL reaction of T cells while not increasing the risk of severe
GvHD (119). But leukemic cells can also hide HLAmolecules and
then escape T cells surveillance. In this situation, NK cells can be
fundamental to eliminate tumorous cells because under standard
circumstances, NK cells are inhibited by HLA molecules. When
HLA molecules are missing, NK cells do not receive an inhibition
signal and wait to be activated. Activating signal can come from
NK cells-related activating KIR ligand-receptor in case of a match
between patient and donor (120), or it can come from activating
NKG2D receptor, where ligands match, mismatch or even their
polymorphisms can play a crucial role (121). But there are still
many unanswered questions, like which specific effect individual
polymorphisms play? And do we know some particular
polymorphisms which could influence HSCT outcome, or if
match or mismatch in NKG2D ligands between donor and
recipient influence HSCT?
MICA and HSCT Outcome
Theoretically, the mismatch between donor and patient inMICA
should lead to impaired NK cell, and T cell activation as the
ligand is not recognized by the receptor. The clinical effect in
patient with mismatched donor then should show a lower GvL
effect worsening overall survival, and on the other hand, a lower
risk of GvHD could be expected.
Indeed, Fuerst et al. described a higher risk of relapse (lower
GvL effect) in the donor-recipient mismatch ofMICA. His study
was focused on match/mismatch in one amino acid –methionine
or valine – at position 129 ofMICA, calledMICA-129 Met or Val
(122). Based on his data, MICA-129 mismatch can also lead to
higher non-relapse mortality overall, meaning mostly aGvHD
(122). According to Parmar and coworkers, aGvHD in patients
with mismatched MICA is triggered by ab T cells. They
speculate that these cells’ response to MICA allo-antigens is
similar to mismatched HLA antigens present on APC (123). It is
worth mentioning that overall survival (OS) rates were lower in
the case of MICA-129 mismatch, but OS rates were similar for
matched and mismatched MICA pairs at allele level (122). We
can then speculate that it is amino acid at position 129, which
plays the most important role in HSCT outcome and MICA
match/mismatch. Focusing on MICA alleles generally, it has
been described multiple times that donor-recipient match leads
to a lower risk of aGvHD (122–124). We can use similar logic
also to cGvHD, whose incidence is increased in transplant pairs
mismatched for MICA (124). Compared to GvHD occurrence,
data regarding the disease relapse is not consistent across the
literature. Unlike Fuerst, Carapito et al. described lower risk of
relapse in transplant pairs mismatched for MICA (124). A
similar result regarding the relapse and mismatch in MICA
between patient and donor was described by Parmar et al.
(123). In this study focused on myeloid leukemias, 3-year
cumulative incidence of relapse in patients with MICA
mismatched vs MICA matched graft was higher for patientsMarch 2021 | Volume 12 | Article 651751
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matched graft) (123). Here authors correlated stronger GvHD
with a lower risk of relapse and thus higher GvL effect, also
corroborated by other studies (125, 126).
The impact of the type of amino acid at position 129 (MICA-
129Met orMICA-129Val) was described to play a role in HSCT
not only from match/mismatch point of view. MICA-129Met
isoform binds NKG2D receptor with higher affinity than
MICA-129Val isoform, which leads to stronger activation of
NK cells – it stimulates NK-cells mediated cytotoxicity more
effectively, it triggers stronger IFNg release and a faster
activation of CD8+ T cells (121). On the other hand, this
stronger and faster reaction leads to quicker NKG2D
downregulation and reduction of effectivity of NK cells
followed by lower activation of CD8+ T cells, a phenomenon
called exhaustion of NK cell activity (121). On the other hand,
MICA-129Val isoform induces weaker but longer-lasting NK
cell reactivity (121). Consistent with this knowledge is the fact
that homozygous carriers of MICA-129Met alleles have an
increased risk to experience acute GvHD (121), and
homozygous carriers of MICA-129Val alleles have an
increased risk to experience chronic GvHD (127).
Furthermore, homozygotes MICA-129Met alleles carriers are
at higher risk to experience relapse due to the exhaustion effect
(121, 127). Despite the higher risk of relapse and aGvHD,
patients withMet/Met have better overall survival than Val/Val
carriers (121, 128). Martin et al. in 2020 implicated that patients
receiving MICA-129Met graft have decreased risk of non-
relapse mortality after HSCT (129). Another study describes a
higher risk of CMV infection or reactivation and a higher risk
of non-relapse mortality in patients receiving a graft from a
donor having MICA-129Val/Val (130). The role of an isoform
of MICA-129 may also affect the serum level of soluble MICA
(sMICA) (131). In vitro experiments show that MICA-129Met
clones release more soluble MICA and a higher proportion of
the MICA-129Met variant is retained in intracellular
compartments which could influence HSCT outcome, but it
needs to be confirmed in experiments using patients’ samples
(131). The effect of soluble MICA on chronic GvHD
development was described by Boukouaci et al. (127). The
patients with sMICA > 80 pg/mL after transplantation have a
higher risk of developing cGvHD than patients with sMICA <
80 pg/mL. Soluble MICA seems to be an even more important
parameter than allele isoform of MICA-129 as patients with
sMICA > 80 pg/mL have always higher risk of cGvHD
development regardless of MICA-129 variant than patients
with sMICA < 80 pg/mL (127).
MICB and HSCT Outcome
Besides MICA, alsoMICB were observed to play a role in HSCT,
as their match or mismatch seems to be a very important player
in HSCT complications (124). Carapito et al. described the
impact of mismatch of amino acid – isoleucine (Ile) and
methionine (Met) – at position 98 within MICB (MICB-98)
between donor and patient on GvHD and on overall survival
(OS) affected by CMV (132). Although this mismatch occurs in
approximately 6% of transplantations, such transplantation ofFrontiers in Immunology | www.frontiersin.org 9hematopoietic stem cells from MICB-98 mismatched but
otherwise fully HLA and MICA matched donor increases risk
of both acute and chronic GvHD development. By monitoring
the effect of match/mismatch in MICB-98 on overall survival
affected by CMV, they found that MICB-98 match significantly
reduced the effect of CMV status on overall survival. Patients
with matched graft had similar OS, regardless of CMV status. But
when the patient received a mismatched graft and was CMV
positive, there was fundamentally worse OS than for CMV
negative patient with a mismatched graft (132). Match in
MICB-98 between patient and donor is then another parameter
which would be good to monitor and which could help to select
the optimal donor.
ULBP and HSCT Outcome
Among ULBPs investigated, only the role of ULBP6 in allogeneic
stem cell transplantation has been described. Antoun et al.
defined 2 common ULBP6 alleles, ULBP6*001 or ULBP6*002.
Patients with allele ULBP6*002 had better 8-year relapse-free
survival (44% vs. 25%, p < 0.001) and better 8-year OS (55% vs.
39%, p = 0.003) than patients lacking this allele (102).
Surprisingly, the protein of allele ULBP6*002 triggers lower
cytotoxicity of NK cells. This seemingly controversial result can
be explained by soluble ULBP6*002 which is attached to NKG2D
with high affinity, disabling other NKG2D ligands to activate NK
cells and limiting repeated triggering of NKG2D receptor (133,
134). Zuo et al. explain reduced survival after HSCT of carriers of
ULBP6*001 variant by reduction of tumor antigen availability or
elimination of antigen-presenting cells or T cells, which
suppresses the subsequent development of alloreactive T cell
immunity (133). These results need to be confirmed in
further studies.CONCLUSIONS
As described, AML cells can deploy multiple protective
mechanisms to survive and to spread. Part of these
mechanisms involve NK cells and their recognition abilities.
But these general mechanisms are not affecting all NK cells in
the same way. Because NK activity is based on the balance of
inhibitory and activating signals mediated by an interaction
between ligands and receptors, AML cells downregulate some
ligands for one of the most critical activating receptor NKG2D.
In various diseases, it has been described that polymorphisms
of NKG2D ligands are positively associated with their
development. For example, an allelic variant of MICA-129 was
described to be associated with systemic lupus erythematosus
(135), MICA*002 allele can have an effect in reducing the risk of
primary sclerosing cholangitis (136),MICB*004 allele is associated
with rheumatoid arthritis (137) and expression of ULBP3 is
upregulated in patients with alopecia areata (138). With all
above associations and with first findings of the relationship
between the different allelic distribution of selected NKG2D
ligands in AML patients compared to healthy donors, we believe
that individual polymorphisms could have a broader impact onMarch 2021 | Volume 12 | Article 651751
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studies should be done to draw relevant conclusions.
The importance of NKG2D ’ and NKG2D ligands ’
polymorphisms is also evident in studies that showed their
correlation to patients’ outcome after HSCT. Additional markers
may help to estimate the probability of post-transplant
complications. Current data show that a match between patient
and donor in MICA and in MICB can also be beneficial, but we
still know very little about ULBP and about all polymorphisms
playing a role in HSCT outcome. It becomes paramount to
understand of the pathophysiological role of NKG2D and
NKG2D ligands, and their role on HSCT outcome. This can be
fundamental for donor selection to improve overall survival with
strong GVL affect and low GvHD. This should be now feasible,
with NGS sequencing becoming easier, more sensitive, and
affordable for larger cohorts.Frontiers in Immunology | www.frontiersin.org 10AUTHOR CONTRIBUTIONS
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